1. Response Rates and Adverse Event Rates in Phase II Trial%
100 mg/m2qw,
3/4wks
150 mg/m2qw,
3/4wks
100 mg/m2q3w
Nab-paclitaxel
docetaxel
Adapted from Gradishar et al. EBCC , abstract 409.

2. Subset Analysis of Phase II CA-024 Trial and Phase III CA-012 Trial
Every three weeks
Weekly
300 mg/m2
n=76
260 mg/m2
n=229
150 mg/m2
n=74
100 mg/m2
Received as first-line therapy (%)
100 43
ORR (%) 46 33 74 63
Median PFS, months
10.9
5.2
14.6
7.5
Median OS, months NA
14.9
Grade 4 neutropenia (%)* 5 9
Grade 3 peripheral neuropathy (%) 17 10 14 8
Data from CA-012 were previously reported (Gradishar et al. J Clin Oncol 2005;23: ).
NA: Not available because data not yet mature for phase II study.
*Grade 4 neutropenia based on central laboratory data.
Adapted from O’Shaughnessy et al. EBCC , abstract 416.